Sample-Efficient Adaptation of Drug-Response Models to Patient Tumors under Strong Biological Domain Shift

Camille Jimenez Cortes, Philippe Lalanda, German Vega Université Grenoble Alpes (UGA), France · 2026

Read Sample-Efficient Adaptation of Drug-Response Models to Patient Tumors under Strong Biological Domain Shift by Camille Jimenez Cortes, Philippe Lalanda, German Vega Université Grenoble Alpes (UGA), France (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2603-16185.txt.

Introduction

Jimenez, Lalanda, and Vega study how drug-response models can adapt to patient tumors. Models trained on cell lines often fail on real tumors. Their fix splits learning into stages. First, cell and drug features are learned from unlabeled data with autoencoders. Next, the features are matched to drug response in cell lines. A few labeled patient cases then tune the model. Gains were clearest when patient labels were scarce.

Catalog record

CREATORCamille Jimenez Cortes, Philippe Lalanda, German Vega Université Grenoble Alpes (UGA), France
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE39703
LICENSEhttp://creativecommons.org/licenses/by/4.0/
RIGHTSCC BY
SOURCEarXiv

Source: https://arxiv.org/abs/2603.16185

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Sample-Efficient Adaptation of Drug-Response Models to Patient Tumors under Strong Biological Domain Shift Camille Jimenez Cortes, Philippe Lalanda, German Vega Université Grenoble Alpes (UGA), France Abstract Abstract Predicting drug response in patients from preclinical data remains a major challenge in precision oncology due to the substantial biological gap between in vitro cell lines and patient tumors. Rather than aiming to improve absolute in vitro prediction accuracy, this work examines whether explicitly separating representation learning from task supervision enables more sample-efficient adaptation of drug-response models to patient data under strong biological domain shift. We propose a staged transfer-learning framework in which cellular and drug representations are first learned independently from large collections of unlabeled pharmacogenomic data using autoencoder-based representation learning. These representations are then aligned with drug-response labels on cell-line data and subsequently adapted to patient tumors using few-shot supervision. Through a systematic evaluation spanning in-domain, cross-dataset, and patient-level settings, we show that unsupervised pretraining provides limited benefit when source and target domains overlap substantially, but yields clear gains when adapting to patient tumors with very limited labeled data. In particular, the proposed framework achieves faster performance improvements during few-shot patient-level adaptation while maintaining comparable accuracy to single-phase baselines on standard cell-line benchmarks. Overall, these results demonstrate that learning structured and transferable representations from unlabeled molecular profiles can substantially reduce the amount of clinical supervision required for effective drug-response prediction, offering a practical pathway toward data-efficient preclinical-to-clinical translation. Introduction Predicting drug response from molecular profiles is a central goal of precision oncology, with the promise of guiding therapeutic decisions based on tumor-specific characteristics. Large-scale pharmacogenomic screening efforts on cancer cell lines have enabled the development of increasingly accurate machine-learning models by pairing molecular features with measured drug sensitivities 7 . These resources have become a cornerstone for computational drug-response prediction, providing standardized, data-rich environments for model training and benchmarking. Despite this progress, translating models trained on in vitro cell lines to patient tumors remains a major challenge. Cell lines represent simplified biological systems that differ substantially from primary tumors in terms of cellular heterogeneity, microenvironmental context, and clinical confounders 9 . As a result, predictive models that perform well on cell-line benchmarks often exhibit limited generalization when applied directly to patient data. This preclinical-to-clinical gap continues to constrain the practical impact of drug-response prediction (DRP) models in real-world oncology settings. From a machine-learning perspective, this limitation can be framed as a problem of domain shift. Models are typically trained in a source domain defined by cell-line molecular profiles and screening conditions, while deployment occurs in a target domain corresponding to patient tumors. Differences in data distributions between these domains—arising from biological variability, experimental protocols, and measurement platforms—violate the assumptions under which standard supervised learning guarantees generalization 5 , 4 . Addressing such shifts is therefore essential for reliable patient-level prediction. A growing body of work has explored transfer learning and domain adaptation (DA) strategies for DRP, including adversarial alignment, discrepancy minimization, and representation learning approaches 10 , 13 . Among these, autoencoder-based methods have attracted particular interest due to their ability to learn compact latent representations from high-dimensional molecular data 19 . Several models jointly encode cellular omics and drug features using autoencoders coupled with supervised predictors, achieving strong performance on cell-line benchmarks. For example, DeepDRA integrates multi-omics cell profiles with drug descriptors and molecular fingerprints through modality-specific autoencoders trained end-to-end with a prediction network 17 . However, such single-phase training strategies tightly couple representation learning and task supervision and rely almost exclusively on labeled cell–drug pairs, thereby limiting the exploitation of large collections of unlabeled molecular data. In clinical settings, labeled patient data are inherently scarce, making it unrealistic to expect large supervised training sets in the target domain. Consequently, the key practical question is not whether a model achieves state-of-the-art performance when trained and evaluated on cell lines, but whether it can be adapted efficiently to a new biological domain using only a small number of labeled patient samples. Few-shot learning provides a natural framework to address this challenge by enabling rapid adaptation of pretrained models with minimal supervision 16 . While few-shot approaches have shown promise for DRP in patient-derived tumor cells and xenograft models, it remains unclear under which conditions representation learning genuinely improves adaptation efficiency rather than merely enhancing in-domain accuracy. In this work, we investigate whether explicitly separating representation learning from task supervision can enable sample-efficient adaptation of DRP models to new domains, even when direct in vitro performance remains comparable to existing approaches. Our focus is therefore not on maximizing in-domain accuracy on cell-line benchmarks, but on minimizing the amount of target-domain supervision required to achieve reliable adaptation under strong biological domain shift. We hypothesize that unsupervised pretraining on large collections of unlabeled molecular profiles can yield structured and transferable representations that accelerate learning in the target domain, while offering limited benefit when source and target distributions overlap substantially 24 . To test this hypothesis, we propose a staged transfer-learning framework based on autoencoder-driven representation learning and evaluate it across a spectrum of settings characterized by increasing levels of distribution shift, ranging from in-domain leave-out protocols to cross-dataset transfer and patient-level few-shot adaptation. Through this analysis, we aim to clarify when representation learning improves DRP in practice and to quantify its impact on data efficiency under clinically realistic constraints. Contributions and paper organization. This work makes three main contributions. First, we propose a staged transfer-learning framework that explicitly separates unsupervised representation learning, task-specific alignment, and few-shot clinical adaptation for DRP. Second, we demonstrate through a systematic experimental analysis that, although unsupervised pretraining yields limited gains for direct in vitro prediction, it substantially improves few-shot adaptation to patient tumors, reducing the number of labeled target samples required for effective transfer. Third, we link these performance patterns to latent-space geometry, providing mechanistic insight into when and why representation learning is beneficial under strong biological domain shift. The remainder of the paper is organized as follows. Section 2 reviews related work on DRP and domain shift. Section 3 presents the proposed framework. Section 4 describes the experimental setup. Section 5 reports the results, and Section 6 discusses their implications, limitations, and future directions. Related Work A central challenge in applying machine-learning models to biomedical data is their sensitivity to changes in data distribution. Models are typically trained in controlled, data-rich environments (source domains) but are often deployed in settings where data distributions differ substantially (target domains), such as independent cohorts or patient populations. These discrepancies, commonly referred to as domain shift, arise from biological heterogeneity, experimental protocols, and population-specific effects, and can severely degrade predictive performance. Formally, a domain is defined as a joint distribution D=P(X,Y) over inputs X and labels Y 5 , 4 . Domain shift occurs when source and target domains differ, i.e., P(X_{S},Y_{S})\neq P(X_{T},Y_{T}) , due to changes in input distributions (covariate shift), label distributions (label shift), or their conditional relationship (concept shift) 2 , 28 . In biomedical applications, such shifts are particularly pronounced and often unavoidable. DRP exemplifies this problem. Models trained on large-scale in vitro pharmacogenomic screens operate in a domain that differs fundamentally from that of patient tumors. While cell-line datasets provide abundant and standardized molecular profiles, patient data

Read the complete text